Edward Hurwitz

Edward Hurwitz General Information

Biography

Mr. Edward Hurwitz serves as Board Member at Dyne Therapeutics. He served as a Managing Director at MPM Capital. Mr. Edward serves as a Board Member at ReCode Therapeutics. He also serves as Chief Financial Officer at Turmeric Acquisition Corp. He is an Angel Investor. He brings to this role a track record of overseeing innovative investment funds, sourcing investment opportunities, and working with portfolio companies to develop innovative products and exceed financial goals. He was most recently the Founder and Managing Director of Precision BioVentures LLC where he focused on developing novel investment strategies and building a portfolio of businesses. While there, he co-founded Viewpoint Therapeutics, an innovative ophthalmology company. Before this, he was a Director of two funds at Alta Partners - Alta BioPharma Management III and Alta Partners Management VIII. He is currently a board member of Applied Genetic Technologies Corporation, and Macrogenics, Inc. He served as a board member at Viewpoint Therapeutics. While at Alta, he also led investments and is a Board Member of Avid Radiopharmaceuticals (acquired by Lilly), Calistoga Pharmaceuticals (acquired by Gilead), Cara Therapeutics, FoldRx Pharmaceuticals (acquired by Pfizer), Taligen Therapeutics (acquired by Alexion). Throughout his career, he has been a Senior Vice President and CFO of Affymetrix, a pioneer microarray supplier, and a biotechnology research analyst for both Robertson Stephens and Company and Smith Barney Shearson.